Modality
Nanobody
MOA
STINGag
Target
TNFα
Pathway
Complement
PsA
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
Jan 2019
→ May 2031
Phase 1Current
NCT06393471
995 pts·PsA
2019-01→TBD·Completed
NCT05348702
1,372 pts·PsA
2025-08→2031-05·Active
2,367 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-125.1y awayInterim· PsA
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1
Complet…
P1
Active
Catalysts
Interim
2031-05-12 · 5.1y away
PsA
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06393471 | Phase 1 | PsA | Completed | 995 | NT-proBNP |
| NCT05348702 | Phase 1 | PsA | Active | 1372 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα |